

SUPPLEMENTAL FILES

Supplemental table 1: Description of Million Veteran Program (MVP) cohort

Supplemental table 2: Description of PRACTICAL consortium cohorts

Supplemental table 3: Association of family history with prostate cancer outcomes in MVP and PRACTICAL cohorts

Supplemental table 4: Coefficients in final P-CARE model

Supplemental table 5: Association of P-CARE model with prostate cancer outcomes in genetic ancestry strata in MVP

Supplemental table 6: Association of P-CARE model with prostate cancer outcomes in race- and ethnicity-stratified subgroups in MVP

Supplemental figure 1: Odds of prostate cancer in All of Us Research Program by P-CARE category

Supplemental file 1: Variants included in final PHS₆₀₁

Supplemental file 2: Template of laboratory report package for ProGRESS clinical trial

	Cohort				
	All	African	European	American	East Asian
Participants, number					
All participants	585,418	105,014	420,722	50,590	9,092
Prostate cancer	68,618	16,178	48,178	3775	487
Metastases from prostate cancer	6606	1726	4467	369	44
Death from prostate cancer	1709	364	1250	87	8
Age demographics, years					
Age at enrollment, median (IQR)	65 (56, 71)	60 (52, 66)	67 (59, 73)	59 (45, 68)	55 (40, 67)
Age at diagnosis, median (IQR)	67 (62, 72)	63 (58, 68)	68 (63, 73)	65 (60, 70)	66 (61, 72)
Age at last follow-up, median (IQR)	69 (60, 75)	64 (57, 71)	71 (63, 76)	63 (49, 71)	59 (43, 70)

Supplemental Table 1: Description of Million Veteran Program (MVP) cohort. Ages and distribution of continental population ancestry groups among MVP participants included in analyses. Abbreviations: IQR, interquartile range.

	Cohort			
	COSM	ProtecT	African	Asian
Participants, number				
Total	3279	6411	6253	2320
Controls	1116	4828	3013	1184
Prostate cancer cases	2163	1583	3240	1194
Clinically significant prostate cancer cases ^a	1403	628	1424	716
Fatal prostate cancer cases	278	-	-	-
Participant demographic information				
Age at diagnosis, median (IQR)	70.0 (64.6, 76.5)	63.4 (59.0, 67.0)	62.8 (56.1, 68.1)	68.2 (62.0, 74.0)
Age at last follow-up, median (IQR)	78.1 (72.3, 84.1)	60 (55.7, 64.4)	63.0 (58, 72.1)	72.9 (66.5, 78.0)
Positive family history, n	355	394	999	94
P-CARE				
P-CARE score, median (IQR)	20.36 (19.90, 20.83)	20.16 (19.74, 20.59)	21.04 (20.64, 21.44)	20.10 (19.69, 20.51)

Supplemental Table 2: Description of PRACTICAL consortium cohorts. Participant characteristics of the four PRACTICAL Consortium case-control cohorts used in external validation of P-CARE. ^aClinically significant prostate cancer defined as Gleason score ≥ 7 , PSA ≥ 10 ng/mL, T3-T4 stage, nodal metastases, or distant metastases. Abbreviations: CI, confidence interval; COSM, Cohort of Swedish Men; IQR, interquartile range; P-CARE, Prostate CA Risk and Evaluation; PRACTICAL, Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the Genome; ProtecT, Prostate Testing for Cancer and Treatment; PSA, prostate-specific antigen.

Clinical endpoint	HR (95% CI)
	Univariable model
Any prostate cancer	
MVP	1.77 (1.72 - 1.82)
COSM	1.90 (1.34 - 2.42)
ProtecT	1.21 (0.92 - 1.56)
African	2.50 (2.22 - 2.89)
Asian	1.87 (1.14 - 2.91)
Clinically significant prostate cancer	
COSM	1.74 (1.37 - 2.25)
ProtecT	1.14 (0.81 - 1.58)
African	2.83 (2.29 - 3.37)
Asian	1.46 (0.71 - 2.60)
Metastatic prostate cancer	
MVP	1.42 (1.30 - 1.56)
Fatal prostate cancer	
MVP	1.56 (1.26 - 1.86)
COSM	1.62 (0.92 - 2.55)

Supplemental Table 3: Association of family history with prostate cancer outcomes in MVP and PRACTICAL cohorts. Data are HR (95% CI) for prostate cancer outcomes associated with reporting at least one first-degree family member with prostate cancer. Abbreviations: CI, confidence interval; COSM, Cohort of Swedish Men; HR, hazard ratio; MVP, Million Veteran Program; PRACTICAL, Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the Genome; ProtecT, Prostate Testing for Cancer and Treatment.

Predictor	Coefficient (95% CI)
PHS ₆₀₁	1.09746 (1.0856 - 1.1106)
Family history	0.48881 (0.4640 - 0.5100)
PC1	-0.00277 (-0.0053 - -0.0005)
PC2	0.00069 (-0.0035 - 0.0045)

Supplemental Table 4: Coefficients in final P-CARE model. Estimates of coefficients from LASSO-trained PHS using age at diagnosis of prostate cancer as time to event and PHS₆₀₁, family history, and the first 2 principal components of genetic ancestry as predictors. Abbreviations: CI, confidence interval; PHS, polygenic hazard score; PC, principal component.

Clinical endpoint	N	HR (95% CI)				
		HR _{SD}	HR _{80/20}	HR _{20/50}	HR _{80/5}	HR _{95/5}
Any prostate cancer						
All	585,418	2.04 (1.99 - 2.08)	6.33 (5.95 - 6.71)	0.43 (0.42 - 0.45)	2.75 (2.66 - 2.84)	4.09 (3.89 - 4.29)
African	105,014	1.95 (1.85 - 2.05)	5.83 (5.02 - 6.80)	0.49 (0.45 - 0.52)	2.82 (2.60 - 3.06)	3.75 (3.36 - 4.19)
European	420,722	2.05 (1.98 - 2.12)	5.77 (5.32 - 6.22)	0.43 (0.42 - 0.45)	2.49 (2.38 - 2.58)	3.81 (3.58 - 4.02)
American	50,590	2.04 (1.86 - 2.26)	5.56 (4.37 - 7.05)	0.44 (0.39 - 0.49)	2.45 (2.16 - 2.79)	3.73 (3.12 - 4.45)
East Asian	9,092	2.11 (1.55 - 2.85)	5.81 (2.75 - 11.07)	0.45 (0.31 - 0.61)	2.42 (1.67 - 3.45)	3.88 (2.21 - 6.56)
Metastatic prostate cancer						
All	585,418	2.05 (1.93 - 2.16)	6.50 (5.50 - 7.38)	0.43 (0.40 - 0.46)	2.78 (2.54 - 2.99)	4.17 (3.68 - 4.59)
African	105,014	1.89 (1.65 - 2.19)	5.41 (3.72 - 7.64)	0.51 (0.44 - 0.58)	2.69 (2.17 - 3.38)	3.54 (2.70 - 4.75)
European	420,722	1.94 (1.78 - 2.14)	5.07 (4.07 - 6.43)	0.46 (0.41 - 0.51)	2.32 (2.07 - 2.63)	3.45 (2.91 - 4.12)
American	50,590	2.05 (1.41 - 2.61)	5.83 (2.29 - 10.13)	0.45 (0.33 - 0.68)	2.48 (1.54 - 3.35)	3.83 (1.88 - 5.94)
East Asian	9,092	3.13 (0.58 - 8.53)	61.89 (0.30 - 143.86)	0.53 (0.09 - 1.82)	4.27 (0.54 - 12.89)	17.94 (0.38 - 50.76)
Fatal prostate cancer						
All	585,418	1.95 (1.76 - 2.15)	5.71 (4.33 - 7.30)	0.45 (0.41 - 0.52)	2.59 (2.22 - 2.97)	3.77 (3.05 - 4.57)
African	105,014	1.62 (1.16 - 2.12)	3.78 (1.47 - 7.06)	0.61 (0.45 - 0.86)	2.15 (1.25 - 3.19)	2.67 (1.33 - 4.41)
European	420,722	1.91 (1.63 - 2.18)	4.93 (3.28 - 6.68)	0.47 (0.40 - 0.57)	2.28 (1.85 - 2.68)	3.37 (2.47 - 4.26)
American	50,590	2.16 (0.95 - 3.91)	7.70 (0.89 - 26.12)	0.49 (0.21 - 1.06)	2.67 (0.94 - 5.51)	4.51 (0.91 - 12.09)
East Asian	9,092	8.91E60 (0.93 - 9.39E40)	1.67E142 (0.85 - 1.91E95)	1.46E113 (2.62E-37 - 1.09)	1.73E75 (0.92 - 3.96E49)	7.19E112 (0.88 - 7.36E75)

Supplemental Table 5: Association of P-CARE model with prostate cancer outcomes in genetic ancestry strata in MVP.








Association of P-CARE quantiles with any, metastatic, and fatal prostate cancer in genetic ancestry subgroups within MVP.

Abbreviations: CI, confidence interval; HR, hazard ratio; MVP, Million Veteran Program; P-CARE, Prostate Cancer Risk and Evaluation.

Clinical endpoint	N	HR (95% CI)			
		HR _{80/20}	HR _{20/50}	HR _{80/50}	HR _{95/50}
Any prostate cancer					
All	585,418	6.33 (5.95 - 6.71)	0.43 (0.42 - 0.45)	2.75 (2.66 - 2.84)	4.09 (3.89 - 4.29)
American Indian or Alaska Native	5507	5.99 (2.92 - 10.71)	0.45 (0.34 - 0.61)	2.56 (1.75 - 3.66)	3.91 (2.27 - 6.17)
Asian	6210	8.03 (2.71 - 20.08)	0.40 (0.23 - 0.61)	2.80 (1.66 - 4.63)	4.88 (2.16 - 9.64)
Black or African American	101,920	5.83 (5.05 - 6.83)	0.48 (0.44 - 0.52)	2.80 (2.58 - 3.04)	3.72 (3.33 - 4.17)
Hispanic White	26,037	5.07 (3.36 - 7.27)	0.47 (0.39 - 0.56)	2.32 (1.88 - 2.81)	3.47 (2.59 - 4.57)
Native Hawaiian or Pacific Islander	3042	6.94 (1.42 - 16.58)	0.47 (0.26 - 0.85)	2.69 (1.20 - 4.55)	4.35 (1.30 - 9.01)
Non-Hispanic White	418,387	5.78 (5.32 - 6.18)	0.43 (0.41 - 0.45)	2.49 (2.38 - 2.58)	3.81 (3.58 - 4.02)
Other	8077	7.58 (4.34 - 15.33)	0.41 (0.29 - 0.52)	2.97 (2.25 - 4.42)	4.73 (3.17 - 8.03)
Unknown	16,238	6.66 (4.20 - 9.56)	0.43 (0.36 - 0.52)	2.79 (2.16 - 3.47)	4.28 (2.98 - 5.69)
Metastatic prostate cancer					
All	585,418	6.50 (5.50 - 7.38)	0.43 (0.40 - 0.46)	2.78 (2.54 - 2.99)	4.17 (3.68 - 4.59)
American Indian or Alaska Native	5507	1.93E71 (0.15 - 390.02)	0.55 (0.06 - 2.47)	9.45E36 (0.36 - 23.33)	5.31E53 (0.24 - 87.63)
Asian	6210	∞ (0.17 - 872.47)	0.79 (0.04 - 2.62)	4.51E176 (0.39 - 31.10)	1.38E255 (0.25 - 198.21)
Black or African American	101,920	5.52 ((3.71 - 8.29)	0.50 (0.42 - 0.58)	2.70 (2.16 - 3.47)	3.56 (2.66 - 4.91)
Hispanic White	26,037	3.93 (1.12 - 8.24)	0.57 (0.36 - 0.95)	1.98 (1.06 - 3.01)	2.79 (1.09 - 5.05)
Native Hawaiian or Pacific Islander	3042	1.02E108 (0.08 - 9.70E48)	0.76 (1.05E-19 - 3.37)	2.43E55 (0.26 - 1.13E26)	2.87E81 (0.13 - 9.44E37)
Non-Hispanic White	418,387	5.16 (4.15 - 6.57)	0.46 (0.41 - 0.50)	2.34 (2.09 - 2.66)	3.49 (2.96 - 4.18)
Other	8077	18.10 (0.62 - 95.88)	0.51 (0.12 - 1.24)	3.78 (0.77 - 11.28)	7.99 (0.69 - 30.46)
Unknown	16,238	6.94 (1.89 - 16.69)	0.47 (0.28 - 0.74)	2.74 (1.41 - 4.53)	4.30 (1.63 - 8.51)
Fatal prostate cancer					
All	585,418	5.71 (4.33 - 7.30)	0.45 (0.41 - 0.52)	2.59 (2.22 - 2.97)	3.77 (3.05 - 4.57)
American Indian or Alaska Native	5507	1.95E45 (0.15 - 1.85E40)	0.74 (4.45E-7 - 5.30)	1.55E24 (0.29 - 3.52E21)	1.01E37 (0.20 - 2.32E30)
Asian	6210	3.93E305 (1.00 - 1.56E180)	0.28 (2.72E-69 - 1.00)	6.12E156 (1.00 - 1.54E94)	9.67E216 (1.00 - 1.36E140)
Black or African American	101,920	3.88 (1.35 - 7.47)	0.61 (0.44 - 0.88)	2.16 (1.19 - 3.30)	2.70 (1.25 - 4.58)
Hispanic White	26,037	9.11 (0.34 - 44.08)	0.57 (0.17 - 1.67)	2.64 (0.57 - 7.09)	4.75 (0.44 - 17.74)
Native Hawaiian or Pacific Islander	3042	1.84E92 (0.05 - 1.10E93)	1.05 (2.32E-16 - 4.17)	1.99E45 (0.20 - 1.18E46)	1.38E69 (0.09 - 8.24E69)
Non-Hispanic White	418,387	5.02 (3.39 - 6.89)	0.48 (0.40 - 0.57)	2.31 (1.89 - 2.73)	3.41 (2.53 - 4.36)
Other	8077	5.86E126 (0.01 - 1.88E50)	1.03 (7.48E-4 - 6.95)	2.31E67 (0.10 - 1.16E27)	2.90E97 (0.04 - 2.30E40)
Unknown	16,238	∞ (0.32 - 83.89)	0.63 (0.14 - 1.67)	3.62E199 (0.54 - 11.32)	2.97E285 (0.42 - 28.18)

Supplemental Table 6: Association of P-CARE quantiles with any, metastatic, and fatal prostate cancer in self-reported race and ethnicity subgroups within MVP. Abbreviations: CI, confidence interval; HR, hazard ratio; MVP, Million Veteran Program; P-CARE, Prostate Cancer Risk and Evaluation.

All Ancestries (n=74,331)



Supplemental Figure 1: Odds of prostate cancer in All of Us Research Program by P-CARE category. Shown are the odds ratios for an individual to be diagnosed with prostate cancer in the low and high P-CARE categories, relative to the average P-CARE category, derived from logistic regression models controlling for age. Error bars correspond to the 95% confidence intervals, and the shown ancestries are the predictions provided by All of Us. Abbreviations: P-CARE, Prostate CAncer Risk and Evaluation.